Pharmaceuticals

Parathyroid Disease Treatment Market Developments Shaping Growth Across The Forecast Period

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Parathyroid Disease Treatment Market Expected To Reach Based On Its 2026 Value?

The parathyroid disease treatment market has experienced robust expansion in recent years. This market is projected to expand from $2.37 billion in 2025 to $2.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.2%. Historically, this growth has been driven by an increasing incidence of hyperparathyroidism, insufficient understanding of parathyroid conditions, reliance on traditional hormone replacement methods, a scarcity of sophisticated surgical options, and inadequate hospital pharmacy facilities.

The parathyroid disease treatment market is projected to experience substantial expansion in the coming years. This market is set to reach $3.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This anticipated growth is driven by several factors, including an escalating demand for calcimimetics and bisphosphonates, improvements in parathyroid imaging and diagnostic techniques, the rise of homecare and telemedicine options, favorable regulatory frameworks for precision medicine, and the proliferation of specialty centers dedicated to endocrine disorders. Key trends expected during this period involve the increased uptake of calcimimetics and bisphosphonates, a shift towards parenteral administration over oral for severe conditions, the enlargement of hospital and specialized care facilities, a heightened emphasis on personalized hormone replacement therapies, and the incorporation of lifestyle and nutritional approaches into treatment strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

What Key Factors Are Affecting The Parathyroid Disease Treatment Market Demand?

The expanding occurrence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the parathyroid disease treatment market in the coming years. CKD refers to a prolonged ailment where renal function progressively declines, resulting in mineral imbalances, including calcium and phosphorus. The increasing incidence of CKD mainly stems from the growing prevalence of diabetes, given that sustained elevated blood sugar levels can progressively impair the kidneys’ filtering components, leading to diabetic nephropathy. Treating parathyroid disease is crucial for managing CKD, as it addresses secondary hyperparathyroidism, a common issue in advanced CKD that disrupts calcium and phosphorus equilibrium, contributes to skeletal problems, and fosters vascular calcification. For instance, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, indicated that over one in seven adults in the US, approximately 35.5 million people or roughly 14%, were estimated to have chronic kidney disease in 2023, with nearly 90% of those affected unaware of their condition. Consequently, the increasing prevalence of chronic kidney disease is propelling the growth of the parathyroid disease treatment market.

Which Segment Categories Are Included In The Parathyroid Disease Treatment Market Segment Analysis?

The parathyroid disease treatment market covered in this report is segmented –

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid

3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin

4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)

5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

What Trends Are Shaping The Future Of The Parathyroid Disease Treatment Market?

Leading companies in the parathyroid disease treatment market are prioritizing the creation of innovative products, such as parathyroid hormone prodrugs, to enhance calcium regulation and decrease dosing frequency for individuals with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that transform into active PTH within the body to regulate calcium and phosphate balance. For example, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, obtained US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone (PTH[1-34]), intended for the management of chronic hypoparathyroidism in adults. This daily therapy delivers sustained parathyroid hormone exposure for 24 hours, providing an alternative to traditional calcium and vitamin D supplementation by directly addressing the fundamental hormone deficit. The approval of YORVIPATH highlights the increasing focus on advanced hormone replacement therapies aimed at boosting treatment adherence and achieving improved clinical outcomes for patients with parathyroid disorders.

Who Are The Active Companies Shaping The Parathyroid Disease Treatment Market?

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.

Get The Full Parathyroid Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

Which Region Holds The Highest Market Share In The Parathyroid Disease Treatment Market?

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Parathyroid Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Parathyroid Disease Treatment Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Anti Thyroid Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795